Beam Therapeutics Inc. BEAM
We take great care to ensure that the data presented and summarized in this overview for Beam Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BEAM
View all-
Farallon Capital Management LLC San Francisco, CA9.93MShares$208 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.87MShares$186 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.48MShares$178 Million1.79% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$160 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$95.1 Million72.77% of portfolio
-
Nikko Asset Management Americas, Inc.4.27MShares$89.5 Million1.12% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.4.27MShares$89.4 Million0.06% of portfolio
-
State Street Corp Boston, MA3.44MShares$72.1 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.03MShares$63.4 Million0.01% of portfolio
-
Kynam Capital Management, LP Princeton, NJ2.52MShares$52.8 Million4.14% of portfolio
Latest Institutional Activity in BEAM
Top Purchases
Top Sells
About BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Insider Transactions at BEAM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 03
2025
|
Amy Simon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
876
-1.33%
|
$17,520
$20.12 P/Share
|
|
Jul 01
2025
|
Amy Simon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
374
-0.57%
|
$5,984
$16.94 P/Share
|
|
Apr 02
2025
|
Amy Simon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,997
-24.21%
|
$356,949
$17.73 P/Share
|
|
Apr 01
2025
|
Amy Simon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,566
-9.93%
|
$172,188
$18.35 P/Share
|
|
Apr 01
2025
|
Bethany J Cavanagh SVP, Finance and Treasurer |
SELL
Open market or private sale
|
Direct |
3,015
-6.34%
|
$54,270
$18.35 P/Share
|
|
Apr 01
2025
|
Giuseppe Ciaramella President |
SELL
Open market or private sale
|
Direct |
7,434
-3.76%
|
$133,812
$18.35 P/Share
|
|
Apr 01
2025
|
John M. Evans CEO |
SELL
Open market or private sale
|
Direct |
30,663
-3.02%
|
$551,934
$18.35 P/Share
|
|
Apr 01
2025
|
Christine Bellon Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,674
-4.61%
|
$102,132
$18.35 P/Share
|
|
Mar 31
2025
|
Christine Bellon Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+13.99%
|
-
|
|
Mar 31
2025
|
Amy Simon Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+22.21%
|
-
|
|
Mar 31
2025
|
John M. Evans CEO |
BUY
Grant, award, or other acquisition
|
Direct |
77,500
+7.09%
|
-
|
|
Mar 31
2025
|
Bethany J Cavanagh SVP, Finance and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+17.38%
|
-
|
|
Mar 31
2025
|
Giuseppe Ciaramella President |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+15.04%
|
-
|
|
Feb 18
2025
|
Bethany J Cavanagh SVP, Finance and Treasurer |
SELL
Open market or private sale
|
Direct |
6,287
-14.35%
|
$220,045
$35.0 P/Share
|
|
Feb 14
2025
|
Christine Bellon Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.85%
|
$340,000
$34.0 P/Share
|
|
Feb 14
2025
|
Christine Bellon Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.12%
|
$70,000
$7.22 P/Share
|
|
Jan 30
2025
|
John M. Evans CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.6%
|
$810,000
$27.02 P/Share
|
|
Jan 02
2025
|
Bethany J Cavanagh SVP, Finance and Treasurer |
SELL
Open market or private sale
|
Direct |
1,117
-2.49%
|
$26,808
$24.68 P/Share
|
|
Jan 02
2025
|
Christine Bellon Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,241
-1.19%
|
$29,784
$24.68 P/Share
|
|
Dec 31
2024
|
Sravan Kumar Emany Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 253K shares |
|---|---|
| Exercise of conversion of derivative security | 105K shares |
| Open market or private sale | 290K shares |
|---|